Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Mol Cancer Res. 2018 Sep 28;17(2):508–520. doi: 10.1158/1541-7786.MCR-18-0557

Figure 6: The ability of wild type and mutant IDH1 overexpression to rescue HT1080 cells treated with AGI-5198, in vitro and in vivo.

Figure 6:

A, Immunoblots depict WT.IDH1 or Mut.IDH1 overexpression in HT1080.HuR(+/+) or HuR(−/−) knockout cell lines. B, PicoGreen drug sensitivity assays in HT1080 cells treated with AGI-5198. WT.IDH1 (top panel) or Mut.IDH1 (bottom panel) were stably overexpressed (or empty vector) in HT1080.HuR(−/−) and HT1080.HuR(+/+) cells. IC50 values are provided in table. C, Xenograft growth of HT1080.HuR(−/−) cells with stable overexpression of WT.IDH1 or MT.IDH1, treated with vehicle or AGI-5198. Each data point represents the mean ± SEM (n=8 per group). * p ≤ 0.05, ** p < 0.01; *** p < 0.001.